Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flu vaccine study aims to uncover why some COPD patients suffer more flare-ups

NCT ID NCT04901455

Completed Knowledge-focused Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the nasal immune system of people with COPD reacts to a live flu vaccine (FluMist). Researchers compared those who have frequent COPD flare-ups to those who do not, to see if differences in immune response or viral replication might explain the flare-ups. The study involved 24 participants and measured immune markers and viral clearance over three days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Live attenuated influenza vaccine (LAIV, FluMist)
What this could lead to
If successful, this could help identify why some COPD patients have more frequent flare-ups and point toward better prevention strategies.
What could go wrong
This is a very early, small study (24 participants) focused on immune markers, not on treating or preventing COPD. Results may not lead to any direct benefit for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

  • Eastowne Medical Office Building

    Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.